IJPSR (2024), Volume 15, Issue 1 (Review Article)

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Received on 04 April 2023; received in revised form, 14 July 2023; accepted, 21 November 2023; published 01 January 2024

# A COMPREHENSIVE REVIEW ON REGULATION CONCERNS FOR IMPORT AND EXPORT OF PHARMACEUTICAL DRUGS AND GENETIC PRODUCTS IN INDIA, BRITAIN AND SWITZERLAND

S. Princely Ebenezer Gnanakani [*1], L. N. Srilekha [2], K. P. S. Praneetha [1] and G. Sumalatha [3]

Department of Pharmaceutical Biotechnology [1], Department of Regulatory Affairs [2], Department of Pharmacology [3], Vikas Institute of Pharmaceutical Sciences, Rajahmundry - 533102, Andhra Pradesh, India.

**Keywords:**

Biosimilars, Switzerland, Brazil, India, Import, Export

**Correspondence to Author:**
**Dr. S. Princely E. Gnanakani, M. Pharm., Ph.D.,**

Professor,
Department of Pharmaceutical Biotechnology, Vikas Institute of Pharmaceutical Sciences, Rajahmundry - 533102, Andhra Pradesh, India.

**E-mail:** princely.biotech@gmail.com

**ABSTRACT:** Biopharmaceutical technologies used to create biodegradable materials from biological agents fall within a broad spectrum. The production of bioproducts has grown cleaner and more dependable with the adoption of novel biotechnological approaches. The original study objective was to investigate the legal difficulties surrounding the purchase and sale of biological as well as pharmaceutical products. The production, advancement, and application of biosimilars in medical care are all governed by a legal regime. Guidelines are collections of requirements that producers must adhere to guarantee the efficacy and effectiveness of pharmaceuticals as well as the highest possible consumer security against newly produced goods. Control of biopharmaceuticals entails a comprehensive strategic plan to guarantee superior levels of security and performance. The research concentrates mainly on the trade in and out of drugs from Switzerland, Brazil, and India. International drug manufacturers are now given a stronger legal base on which to introduce novel drugs to the marketplace. This licensing process for new pharmaceuticals can take a year or longer because the healthcare regulatory structure is becoming increasingly complex. Legislation and regulations are always evolving, which is raising the need for regulation of health specialists to keep up with the demands of enterprises amid worldwide business and to assist the drug industry in successfully exporting its pharmaceutical devices to many nations. Imports as well as exports are crucial for the expansion and advancement of economic systems since not all nations possess the assets and knowledge necessary to create a wide assortment of products and services.

**INTRODUCTION:** The World Health Organization (WHO) defines pharmaceutical drugs as drugs made from microbes, plasma, or other living components, and their production processes may involve a combination of the following aspects: Microbe development, isolates in various substrates, utilizing eukaryotes, biomolecules derived from cells, such as human, animal, and plant tissues, as well as items manufactured using R-DNA or myeloma future technologies, and the development of microbes in embryos or any other living creatures are a few examples [1].

Currently, there are a large number of reference papers published by WHO, including teaching materials, recommendations, other generic materials. These publications offer recommendations and advice to the authorities, producers, and consumers of genetic therapies. Although a lot of these materials focus on the manufacture and management of vaccinations as biological goods, there are additionally materials

QUICK RESPONSE CODE

DOI: 10.13040/IJPSR.0975-8232.15(1).20-34

This article can be accessed online on www.ijpsr.com

DOI link: https://doi.org/10.13040/IJPSR.0975-8232.15(1).20-34

pertaining to the manufacturing and management of transgenic DNA-based biopharmaceuticals. Moreover, standard formulations are offered, including transgenic clotting factors, hormonal compounds, and chemokine factors. There isn't an agreement between these benchmark organisations again for nations that make up the Region on certain key concepts utilized and the processes for the regulatory oversight of biopharmaceuticals, even though many duly authorized are currently available from the WHO, the European Commission of Medications (EMEA), and the World Congress on Harmonising linked to biopharmaceutical and genetic product lines [2, 3]. As a result, genetic engineering has gained recognition as a crucial technique for the twenty-first decade in numerous fields, with the improvement of public health being one of its primary applications. A policy with a 30-point planning process was adopted by the European Commission in 2002, and it urged the continent's individual nations to promote genetic development in drug companies. Improved regulations and a particular strategy were also given attention [4].

**The Value of both Imports and Exports:** The international demand was widened, and economic systems were boosted through exports and imports. Each nation has unique benefits when it comes to assets and knowledge. For instance, some nations have plenty of natural assets like fossil energy, lumber, rich soil, and valuable metals and stones, although other nations lack numerous of these assets.




**FIG. 1: FUNCTIONS OF CDSCO**

Furthermore, certain nations possess super-sophisticated facilities, school standards, and currency sectors that enable them to participate in complicated manufacturing and technical developments, whereas many nations lack such advancements. With 11 Seaport headquarters spread across the nation, the Central Drugs Standard Control Organization (CDSCO) manages the trade in and out of medicines in the nation.

The preceding legislation and regulations were used by CDSCO to control the production, distribution, importation, exportation, and medical trials of pharmaceuticals in India [5] **Fig. 1**.

- Drugs and Cosmetics act, 1940 and Rules, 1945.
- Pharmacy act, 1948
- Drugs and Magic Remedies act, 1954.
- Medicinal and Toilet Preparation act, 1956.
- Narcotic and Psychotropic Substances act, 1985.
- The Drugs (Prices Control) order, 1995.

**Process for Importing and Registering Medicines:**

**Design and Processing Parameters:**

**Import Permit:** A registration for an importation permit must be submitted to the licensing agency in form 8 for prescription medications except Schedule X and also in form 8-A for Schedule X drugs.

It must be produced by the manufacturing company or the company's operator in India who's in possession of the reselling licenses for the selling or distribution of the medication. Each form 8 or form 8-A permit form that was submitted with a photocopy of the Registration Card granted per Regulation 27-A in form 41; Despite circumstances that must be documented in detail, the national government may, in cases of emergency, issue import licences in forms 10 or 10-A while issuing register certificates as required by Regulation 27-A. In the event that the initial licence was tampered with, destroyed, or lost, a charge of 250 INR must be charged to obtain a replica [6-8].

**Certified Copy:** In accordance with this guideline, applications for the issuance of Forms of Assessment must be decided to make to the permit in form 40 by the manufacturing company or the operator's authorised representative in India and must include the data and commitments listed in Schedules D-1 and D-II, which must be officially approved by a representative of the manufacturing company.

A legal representative must be signed by the manufacturing company and accredited in front of a First-Class Prosecutor in India or another similar jurisdiction in the company's home nation. The hard copy of this file must be submitted with implementation for a license application.

- ❖ As just an initial deposit for his facilities designed for the manufacture of medications planned for importation, a charge of $1,500 USD must be deposited simultaneously with the request in form 40.
- ❖ For such registering of a particular medicine intended for importing entering and consumption in India, a charge of $1,000 USD was required, as well as an excise duty of just $1,000 USD for required for every subsequent drug [9].

The charges must be paid via a Fantastic customer at the Baroda Bank, Kasturba Gandhi Marg, New Delhi-110001, or a different regional office or branch offices of the Baroda Bank in India, or a different financial institution, as the Central Govt may notify from time to time, in order to just be attributed underneath the Head of Act "0210-Medical and Global Health, 04-Public Care, 104-Fees and penalties."

If the producer was making the payments directly in the nation from which it originated, the charges must be that the petitioner was responsible for paying a charge of $5,000 USD to cover any costs incurred either by the licencing agency or any other individuals who the licencing agency has granted board in just this regard per rule for an assessment or examination of the production facilities or medicines [10-12].




**FIG. 2: IMPORT OF DRUGS**

**Authorises for Pharmaceutical Products Generated by one Candidate:**

**Import:** For the import of many medications or classes of medications produced by an identical producer, only one request needs to be submitted, and only one licence needs to be granted **Fig. 2**. (Supplied furthermore that when a name includes two or even more facilities in various locations producing either identical or alternative pharmaceuticals, a unique Permit must be obtained in regard to pharmaceuticals supplied by each respective company).

**Register Document:** Again, for the importation of multiple medications or classes of medications produced by identical manufacturer, only a request needs to be submitted, and only one Registered Trademark in Forms 41 needs to be granted **Fig. 2**.

**In front of a forms 10 or forms 10-a Licence was issued, the following must be clarified:**

**The Licencing Board must Consider the following Factors before Granting a Licence in Form 10 or Form 10-A:**

- The location in which the supplied drugs would be stored.
- The profession, industry, or line of work that the candidate typically engages in.

- Also, that candidate really hasn't conformed only Acts or all these regulations' requirements,
- He was convicted underneath the Narcotic Drugs and Psychotropic Substances Act, and his licence had previously been suspended or revoked as a result.
- Someone that feels wronged by the licencing agency's decision.

**Authorize:**

**Importing Permit:** The licencing board must provide an importing Permit in Form 10 or Form 10-A, as appropriate, upon receiving a request for an importing Permit in the format & method specified in Regulation 24 and upon having been convinced that the requirements of the Permit, if obtained, would be adhered to. A registration was issued until 3 years from the date it was issued, regardless of whether it was revoked or revoked earlier. A new licence application must be submitted 3 months before the current one expires [13].

**Registration Certificate:** If it was prohibited or revoked earlier, a licensing certificate remains valid for 3 years from the date of its issuance, and a unique authentication certificate was given away for 9 months even before the expiration of the previous certificate.

**Termination and Suspension:** The supplier or operator will have their import permit and certificate of registration stopped or revoked if they break any of the terms. The regulator might, after conferring the maker or holder an opportunity to clarify the reason why the order shouldn't be approved, postpone or revoke it for as long as it considers necessary, either fully or with regard to certain chemicals to which it refers. When the drug product's strength has worn off, it is illegal to import any medications listed on Schedules C and C1. If a substance was outlawed in its country of origin, it cannot be imported into the country unless it is for testing, analysis, or examination purposes.

**Imported Medications:** Part XII of the regulations applies to drugs for veterinary use, while parts IX and X of the regulations apply to all other drugs.

**Packaging of a Patented or Privately Held Drug:** The permit must be secured at a minimum three months prior to the date of importation, and bulk containers must be used for the importation of proprietary or patent medications. One year from the date of issuance, the licence remains in effect [14].

**Novel Medications for Patients' Treatment Supply:**

- No new medication may be brought in from outside the country if it's authorized by a Permit in Forms 11-A and has been given the go-ahead for marketing in the country of origin.
- Any substances or pharmaceuticals supplied with the License must be used by the Licensee.
- The Licensee was expected to keep a record and provide an update towards the regulatory board every six months. The Licensee must grant authorization, regardless of prior notice, to an Inspector appointed by the regulating body.
- The Licensee was required to follow any additional rules published under Chapter 3 of the Act if the regulating authority had given him at least one month's notice.
- The medication must be kept in appropriate storage conditions and administered under the guidance of a licensed pharmacist.
- No more than 100 typical doses of a single medicine may be imported per patient.

**License Application:**

- An application for a novel's import permit medicine in modest quantities, as defined by regulation 122-E, for patient treatment.
- The licensing authority has the right to request any additional information it deems relevant.
- Every form 12-AA registration must be supplemented by a charge of Rs. 100- for a prescription product as well as Rs. 50 for each subsequent drug, which has to be paid using a bill in the Baroda Banking Corporation.

**Removal of the License:** A permit for the importation of limited quantities of a novel drug, as defined in regulation 122-E, may be annulled by the regulator for the purposes that it was originally

given. An operator whose registration has been revoked may plead with the Central Government within three months of the order's date [15].

**Process for Drug Importation:** On such an invitation from an officer assigned by the Central Govt. for this purpose, the Customs Collector was required to take specimens of any opiates in the shipping and send them to the board member of the research lab assigned for this purpose if they had evidence suggesting that any substances in the shipping did not the standards of Chapter 3 of the Regulations and Act.

An importer who has given an undertaking in accordance with the proviso of subrule (1) may be required by the Customs Collector to return the consignment or any portion of it. In this case, the importer shall comply within ten days of getting the notice.

If the assigned laboratory director for the Central Government, or some other officer with his leadership, notifies the customs hoarder that the specimen of any drugs in a consignee were not of quality level or that the substances do not conform with Chapter 3 of the Behave or even the Regulations, or that the breach of the rules was just the same that it's unable to be rectified by the importing country, the customs creditor shall notify the importer [16].

**Drug Registration Requirements Informed 40:**

**A formal Letter:** This includes the list of necessary documentation as well as any other data; it has to be duly endorsed and stamped either by the approver and contain the title and company's mailing address.

**Permission Letter:** The original permission letter, agreed to sign by the board member, company secretary, or another companion of the Indian agent firm, and uncovering the identity and identification of the contracting party to Form 40, authority to act, *etc*., must be presented along with an appropriately self-attested photocopy at the moment of registration.

**Form 40 Challan and TR 6 Challan:** The Local Authorized Agent's name, position, and date must be written on it, together with a completed form that complies with the Pharmaceuticals and Cosmetics Rules. In Annexure-I, there needs to be a performa. Payments must be sent via the Electronic Clearing Service (ECS) from every bank in the nation of origin to the Baroda Bank in New Delhi to use the bank's digital code.

**Power of Attorney:** An Attorney's Power validated in Delhi or by the nation of origin must be used to support any authority granted by a manufacture to his representative in India. The certification needs to be certified either by Indian Embassy in the country involved or by hardcopy must be presented with the petition for a Registration Card (RC).

The Annexure III performs for a Power of Attorney (POA) was attached. The manufacturer's sales operations in India will fall under the purview of the authorised agent. The following must be provided with the Power of Attorney:

- Both the maker and the Indian Agent must sign and stamp it, specifying the names and titles of the authorised signatories.
- All the prescribed drugs must be listed with their names and indications as precisely as possible. The names of the proposed pharmaceuticals must match anyone on Schedule 40, Free Sales Credentials, or Certificates of Pharmaceuticals in compliance with the WHO-GMP testing process (COPP). The manufacturer’s and the Indian Agent's names and addresses on form 40 shall match those on the authority to act. Due to the fact that many locations were in tabular form, the updated POA should be provided whenever the RC was revalidated [16, 17].

**Wholesale Permit:** A certified authentic copy of the form 20B & 21B or Form 21C Retail License for the Distribution or Sale of Medicines issued by the Indian State Licensing Board to the manufacturer or its representative in accordance with the Cosmetics and Drugs Regulations. **Undertaking:** The manufacturer/authorized agent has signed and stamped the CTD Module 1 answering Schedules D (I) requirements, which was enclosed in Annexure IV and specifies the identity and identity of the authorized signatory that must be submitted in line with Performa for Schedule D. (I).

**Annexure V contains a list of the Facility Master File Requirements:**

- Schedule D (II) specifications were outlined in Components 2 through 5 as follows:
- Drug Requirement: The 2nd Category of the Act mandates that imported drugs abide by the requirements outlined in the IP, USP, BP, EP, etc.
- Label submissions: If they follow the labelling claim in IP, they are a faithful duplicate of the Tag in accordance with Rule 96.

**Studies on Medications:** To enroll bulk pharmaceuticals, the laboratory should receive the three subsequent batches, the requirements, the technique of analyses, the Certification of Analysis (COA) assessed in their lab, impurity criteria, indicator substances, and ultimate source, together with its COA where necessary, for assessment and analysis.

**Free Sale Certificate (FSC):** The suggested medicine must be legally sellable and widely promoted in the nation of origin, according to the free sale license.

**Manufacturer's Permit:** A true duplicate of the document proving marketing authorization or manufacture permit from the country's drug governing authority. If there is free-sale documentation accessible, you may indeed send it.

**Certification for Drug Registration:** If appropriate, a copy of the latest Product License Application for the overseas processing facility.

**Re-registration:** In addition to Form 40, POAs, GMP/COPPs, registration credentials, invitations, Drug master files (DMFs), and Licenses, the request must be submitted 9 months before the registered trademark expires. evidence to suggest that the automaker or his legal representative in India will not consider taking whatever disciplinary actions regarding any allergic response, business detachment, governmental regulations, or discontinuation of permission relating to this License Application proclaimed by the regulation agency in the nation of provenance or by any legislative oversight in any additional nation, in which the substance was commercialized or dispersed.

- Alteration to any medication that affects how it was produced, packaged, labelled, tested, or documented according to this Registration Certificate.
- Any adjustment to the company's leadership context, such as modifying the title or location of the plant or registering headquarters.
- Details on medicines that were brought to India well over the prior 3 years.

**How to Apply for a Not Objection Letter (NOC) for the Sale of Restricted Medications, Approved New Medications and Unapproved Drugs:** If the supplier possesses a current registration duplicate in forms 25 and 28, only recognized, unapproved, or prohibited medications from India might well be transported using a No Objection Letter. The specifications were in agreement with the criteria provided by the Health Ministry and the Department of Family Affairs for commercial sale as well as Rule 94 of the 1940 Medicines and Cosmetic Act [17].

**Indian Drug Exporting Regulations:**

**Regulation 94, which Addresses the Branding and Packing of Pharmaceuticals apart from Homoeopathy ones:** The labelling on packaging or boxes of medications intended for exporting must be customised to meet the specific legal standards of the nation where the medication was being shipped. The following information was required for each prescription drug: the medication's names; the company's name, location, and registration number; the batch or lot amount and the expiration. The limitations of Rules 96 to 101 included should not apply to a medicine that was produced to be used, either with or without diluting, and delivered in compliance with such a licensed physician's recommendation, as provided [18]:

- If the drug was to be administered inwardly, the quantity will be listed on the labelling alongside the company's name and place of residence, the participant's name and the prescribed quantity, and the registration number of the prescribed record in the medication record [19].

❖ The words "Only external use" should be printed on the labelling of any prescription that was meant solely for use externally.

**Branding Design Rule 96:** The additional data must still be displayed or handwritten in legible, permanent ink on the labelling of any medication's inner box, in addition to all other packaging that the bottle was packaged in.

The title listed in each authorized monograph and government-abridged versions of pharmaceutical regulations, accompanied by the initials I.P. or the designation or equivalent of the medicine mentioned in the Value Determined of India, preceded by the initials N.F.I.

When there is a global publicly available title for a pharmaceutical that's not mentioned therein, it should be one that accurately describes the drug's genuine composition or where it came from [20, 21].




**FIG. 3: FLOW CHART PROCESS FOR ISSUING NO OBJECTION CERTIFICATE FOR EXPORT**

**Issued by the Department of Health and Family Welfare were Drug Export Regulations [22]:** When awarding NOCs for the manufacturing of novel (unpermitted) medicines designed largely for sale, the following essential considerations must be made:

- A NOC will be provided against each valid export order against which the application was submitted, case by case.
- The application must specify the location of the manufacturing facility for the medicine intended for export.
- Whether exporting batches have previously completed product testing certification or were scheduled to be tested just at ultimate stop must be specified in the request.
- The candidate was required to ensure that none of the medication(s) created with the NOC obtained in compliance with the initial requirement was redirected for local distribution in India **Fig. 3**.
- The candidate must provide data about each shipment despatched, the medication's remaining inventory, and any necessary raw ingredients or precursors that were in their possession and accessible for examination by the relevant people, after fulfilment of the manufactured exports.

- The applicant must make sure that all medications that were not exported were physically destroyed. This should be a requirement of any manufacturing licence that the State licencing body grants to the applicant.

- If the medicine is later outlawed in the nation or in the country from which it was imported, the applicant must make sure that it stops being manufactured or exported.

With around 200 million citizens, Brazil was the most populous and vastest country in South America. Brazil, the eighth-vastest pharmaceutical economy in the globe, is presently a key location for financial growth and has a fantastic future. Since 2000, the Brazilian biopharmaceutical market has undergone increasingly significant and advanced changes as a result of improvements in domestic commerce, consumer demand, and productive capacity. Bio- pharmaceutical businesses from all over the globe were keen to invest in this sizable industry due to Brazil's developing sector [22, 23].

**Manufacturer's Permit:** Any registration for the importation of an unauthorized medicinal product used in the production of a medication must be accompanied by a duplicate of the Assessment criteria bill out from importation that has been properly authorized by the relevant agencies.

**Governing Body ANVISA:** The Portuguese Agencia Nacional de Vigilance Sanitaria53 was shortened to ANVISA, the acronym for the Brazilian Health Surveillance Agency. The Brazilian regulatory body ANVISA was in charge of monitoring and approving products like food, medicine, cosmetics, tobacco, and medical gadgets, as well as keeping ports and airports clean. ANVISA was connected to the Ministry of Health and was developed in 1999 by rule 9.782/1999ANVISA's main objective was to recuperate and safeguard the community's health by outlawing the creation and implementation of structures and goods that pose a threat to the wider population. Regulations for clinical trials and the registration of pharmaceuticals and biologics were created by ANVISA. It was regarded as a financially and administratively autonomous institution and was run by a five-member board. ANVISA became a supervisory affiliate of the International Council on Harmonization (ICH) in November 2016, and since then, the institution has already been striving diligently to concentrate and improve its determination to become familiar with ICH guidelines. The ICH individual countries' CTD form and Brazil's enrollment differ geographically and have certain similarities. There were two main sections in the Brazilian dossier: Administrative Data: This includes all administrative information as well as some requirements for imported goods. Technical Section: This contains annual analysis that researchers have conducted on CTD Modules 2, 3, 4, and 5. These reports provide high-quality, nonclinical, and clinical information [24, 25].

**Entities Involved in Brazil's Authorization Process:** The CONEP (Central), CEP (Local Committee), and ANVISA organisations were responsible for examining and approving the regulatory paperwork needed to begin a clinical investigation in Brazil. Both the CONEP and ANVISA procedures were active at once. The National Commission of Ethics in Research (CONEP) was Brazil's central ethics committee and was tasked with assessing and certifying the clinical trials' ethical components. CONEP was a part of the Ministry of Health [25, 26].

**Rio de Janeiro's Drug Laws:** A novel drug's registration was subject to a number of conditions, including that the "product be recognised as safe and effective" and that "complete data" be provided technical studies and Preclinical and clinical participatory research shall be submitted in conformity with the particular instructions set forth in Council No. 136/2003 in order to obtain marketing authorisation. Contrarily, Brazilian regulators continue to give domestic companies that have not yet conducted a clinical study marketing approvals for innovative medications.

**Aim:** The article's objective was to evaluate the legal difficulties surrounding the import and export of biological and pharmaceutical products.

**Objectives:** The idea was that imports and exports were crucial for the expansion and development of national economies since not every country has the assets and funds required to produce specific products and services.

**Approaches:** The production, advancement, and application of biologics in clinical practice were governed by a regulatory framework. Regulations are sets of requirements that producers must adhere to in order to guarantee the security and efficiency of pharmaceuticals as well as the highest level of public protection from newly produced goods. The regulation of biopharmaceuticals requires a thorough administration plan to ensure appropriate safety and quality requirements [27].

**TABLE 1: IMPORTING AND EXPORTING OF BIOLOGICAL PRODUCTS AND PHARMACEUTICAL PRODUCTS IN INDIA**

| | 2003-2004 | | 2004-2005 | | 2005-2006 | |
|---|---|---|---|---|---|---|
| | **Exporting** | **Importing** | **Exporting** | **Importing** | **Exporting** | **Importing** |
| Division of Fertilization and Chemicals, Division of Petroleum and Chemicals. (Annual report 2006-07) | 74450.0 | 1150.0 | 9263.0 | 1000.0 | 1002.0 | 1945.0 |
| Polymers and petroleum products division. | 15213.0 | — | 17857.0 | — | — | 22116.0 |
| Statement of the advisory committee on medications and medicines for India's economic committee's 11th five-year program | 15213.2 | 2956.0 | 17857.2 | 3169.4 | 21579.0 | 4515.2 |
| IDMA (45th official report, 2007) | 15213.2 | 2956.6 | 17857.2 | 3169.4 | 21579.0 | 455.2 |
| OPPI's 2005 information brief on the Indian healthcare division | — | — | — | — | 198000.0 | 4800.0 |
| EDMA | 143224.2 | 5085.0 | 16681.0 | 5830.0 | — | — |
| Difference between lowest and highest figures (Percent) | 104.2 | 342.2 | 92.8 | 232.1 | 104.4 | 145.2 |

The identification of the medicinal goods was the initial phase of the evaluation. There doesn't even appear to be a defining trend for pharmaceutical drugs in the sources of data that are presently available. According to the ministry of petrochemicals and chemical exports, the volume of prescription medicines shipped was only halfway of the quantity that IDMA and the Advisory Committee on Pharmaceuticals and Therapeutics stated for the 11th Plan. For imports, there was a definite discrepancy here between the least and greatest estimates. By a proportion of much more than three, the Directorate of Petroleum and Chemicals acknowledged a lower number compared to what the BDMA claimed. The striking disparity between both the employment numbers referenced in the Unit of Petroleum refining Financial Survey and all those introduced on its webpage, along with the document of its Taskforce on Pharmaceutical and Drug Products for the 11th Five-Year Strategy, serves as proof of the complete absence of knowledge regarding the problem at every administrative level **Table 1.** The extreme lack of knowledge about the issue throughout the time of the authoritative level was shown by the stark discrepancy here between trade statistics provided in the Dept of Chemicals and Petrochemicals' Financial Statement, including those offered on its webpage, and in the Taskforce on Drugs and Pharmacological treatments' document for the 11th Biennial Plan. Medicines were defined by the division of chemistry as petrochemicals and chemicals such as needles, as well as other diagnostic supplies, blood components, organs, appendages, and related extraction, in addition to therapeutic bandages, treatments, and drug products that comprise more than one chemical composition or component. In fact, the information for medicinal goods being imported and exported supplied by the Director General of Advert Intelligence and Statistics (DGCIS) for Chapter 30 of Indian Trade Classification closely resembles the data that was submitted by the Department in the Financial Statement of the Ministry of Chemicals and Fertilizers of India (ITC). The information compiled in the Financial Statement of the Department of Petroleum and Chemicals, which further makes it appear to just have inferred the information from DGCIS, varies markedly from the economic indicators given in the Report of the Steering Committee on Medicines and Pharmaceuticals for the eleventh-year strategy, which would be obtained from DGCIS (shipments vary enormously by 99.4% and import tariffs vary considerably by 132.1%). The multiple methods

that all these two bodies have authorized may be the cause of this. Curiously, the data presented by the Review Panel and one particular business association, the IDMA, agree. Understanding the factors to be considered when acquiring the information was crucial in order to understand the methods. The only resource that offered an inventory of the products was IDMA [27, 28].

**Brazil's Primary Regulations and Agencies for Exports and Imports:**

**The main Oversight Organisations for this Sector were the Ministry of Health, ANVISA, and the National Institute of Metrology, Quality and Technology (INMETRO):**

**The main Guidelines that Govern this sector are as follows:** The 1988-adopted Brazilian Government guarantees all individuals equal opportunity to engage in activities that advance, safeguard, and enhance their well-being (Article 196). In compliance with Articles 30, I and VII, the City and county legislatures were able to enact wellness legislation at the same time as they had the authority to address wellbeing problems and provide free medical services under Editorial 24, XII, which also delegated the above authority to the Confederation, the Countries, and the Union Territory.

**General Guidelines:** Many essential legislations that have recently been established relate to health care and drug items. The hygienic management of medications, remedies, drugs, and associated commodities was governed by Federal Statute No. 5,991/1973.

The basic rule was Statutory Instrument No. 6,360/1976 (as revised on several occasions, most notably by No. 13,411/2016). The monitoring will encompass an extensive variety of things, including beauty, other cleanliness items, prescriptions, and basic products regulated by Statutory Instrument No. 5,991/1973 (the regulation of sterile supervision). The companies and institutions were granted approval by the Ministry of Health to collect, develop, manufacture, handle, combine, filter, special space, package, restock, import, sell, warehouse, and transfer those goods. The hygienic bodies in the Confederate States still must approve these organizations and businesses. Only those who have registered with and received authorisation from the Ministry of Health were able to use medications and modify their constituent parts.

**Regulatory Authority:** ANVISA, the anarcho-communism of the health ministry under this new framework, backed a variety of legislative initiatives underneath the Health Surveillance. ANVISA was created in accordance with Federal Law No. 9,782/1999. It aimed to progress its organisational objective of safeguarding the government's well-being by encouraging clean and hygienic regulatory oversight of the manufacturing and use of products and services that really were subordinate to patient monitoring, such as the surroundings, practices, input prices, and smart applications, in addition to the legislation of harbours, airfields, boundaries, and mated locations [28].

**Transporting Prescription Medicines:** According to National Organization of Drug store Settlement No. 433/2005, it became the duty of the medicinal expert in a drug public transit firm to guarantee compliance with hygienic regulatory requirements, to only permit the transportation of enrolled prescription drugs by accredited businesses, to configure a potential to be beneficial guide for the travel of prescription drugs, medical drugs, and medical supplies, to train the diverse workforce involved, to demonstrate washing, and to guarantee that all authorised treatments were transported.

**Importing and Exporting:** The Technological Directive on the Transportation of Goods as well as Services for Hygiene Monitoring states that importers were required to get authorization from ANVISA prior to bringing in any goods destined for commerce, industry, or direct consumption. The sanitary authority must standardise services in relation to the required notice; obtaining this includes access or another sort of restriction specified by ANVISA (Chapter II of the Technological Regulation). According to Ordinance / SVS N. 344/1998, the buyer would be obliged to get transit permission with ANVISA in the event of particular banned products 19. The items labelled as pharmaceuticals shall be delivered to the acquiring company's technology team, which is based within the territorial boundaries, for the scientific testing necessary to determine chemical origin, identification, and purity at different stages

of manufacturing or processing. It was going to be essential to bring in those goods using SISCOMEX's Imported Modules (reference RDC n. 74/2016) [29].

**Every Piece of Import Merchandise was Under Hygienic Observation must have Identification on the Exterior Packaging that Includes the following Information:**

**A.** The product's commercial name, if it was a finished good or was sold in bulk, as appropriate;

**B.** The name of the main ingredient in the formulation, if a drug was being imported exclusively.

**C.** The product's technical or common name, biological or chemical name, if it was a core ingredient or resource that was utilised to make medicinal goods;

**D.** The goods packaging's batch numbers or new factory identifier;

**E.** The location, state, as well as nation of both the maker;

**F.** Stowage measures, including those pertaining towards the maintenance of the commodities' or items' purity and identification, like moisture, temperature luminance, and many others.

Importers can't be advertised in Brazil using marking or identifying in either language apart from Brazilian Portuguese, aside from non-commercial importation authorized by Sections IX, X, XII, XIX, XX, and XXI of RDC n. 81/20085. As such, as soon as it met Part XV and RDC n. 208/2018, offering branding in Brazilian Portuguese upon Brazilian territory remained acceptable.

The SISCOMEX platform could still permit the manufacture and sale of products with brands in Brazilian Portuguese that do not adhere to hygienic regulations, albeit with limitations, that also primarily call for the distributor to register a Phrase of Shield and Obligation in anticipation of transferring the products from the deployment through the Brazilian market. (Section XV and RDC No. 208/ 2018). ANVISA might delay or confiscate goods when executing its operational authority (see XXXVI of the technological rules, restrictions, and punishments). If the merchandise reveals any unsolved sanitary difficulties or if sanitary anomalies were suspected, ANVISA will keep the product (awaiting or requirement result of laboratory analysis). A sentence of interdiction could be imposed in addition to retention. If the relevant hygienic body accepts, the articles may be held in customs or given to the importer's security in such cases. When a requirement for microanalysis developed, samples were seized [29].

**Ideal Practises:** The RDCs n. 39/2013, n. 15, n. 56, and n. 4/2008 define the criteria for a certification of standard habits asserting the compliance of a specific resource under Excellent Transportation and Delivery Practices. Necessary procedures for the accreditation of Accordance With the recommendations of Employed To produce, Pharmaceuticals Components, and Medical Supplies were created by the RDC n. 39/2013.

**Biological Substances:** In 2010, new regulatory procedures for replicas and new biological goods were created, and ANVISA revised the regulations for biological products (Resolution No. 55 of December 16, 2010). For unique biological products, the standard pathway was required based on comprehensive documentation submitted by the applicant. The next two regulatory frameworks were developed for comparable biological products.

**Path to Personal Development:** A streamlined dossier may be submitted. The application must include all relevant information regarding quality issues, although it does not need to be comparable. Depending on the information available regarding the pharmacological properties, purity, and effectiveness of the original item, the total number of clinical and non-clinical studies filed may decrease. It had to do at least one Phase III comparison trial comparing it to the original biological product to determine whether it was equivalent, non-inferior, or superior (except for vaccines, hemoderivatives, and biological products for oncological usage).

**Regulatory and Legislative Power:** The requirements for packaging and labelling were outlined in ANVISA's Resolution No. 71 on

December 22, 2009, which was overseen by ANVISA [29].

**Requirements for Information:**
**Minimum Information that must be Included on Packaging Includes:**

- The brand title of the drug (except for generics).
- The title of the main component.
- The marketing approval's owner's name and address.
- The brand name and location where the medication was produced (country, state, and city, in the case of imported products).
- The pharmacist is in charge of the medication's name and registration number.
- The lot number.
- Dates of manufacture and expiration.
- The number approves marketing.
- Details on the weight and volume of the medication as well as the formulas and composition of the drug.

**Pharmaceutical and Biological Product Import and Export in Switzerland:** The Swiss Parliament's National and State Councils were in charge of passing legislation governing pharmaceutical items. The responsibility for establishing and enforcing the restrictions fell on the Swiss Federal Council, Swissmedic (the Swiss Agency for Medicinal Goods), and, to a lesser extent, the cantons. The Federal Office of Public Health oversees the regulation of particular blood products and blood components.

**Manufacturing:** Pharmaceutical products had to be produced with a Swiss medical licence (and adding medicinal products to animal feed). A mandatory cantonal licence or reporting requirements may be used instead of a Swiss medical licence in extraordinary circumstances. Typically, this was the occasion for the manufacturing of lesser quantities of pharmaceutical items that were made in accordance with official, ecclesiastical, or producer-owned formulas and were suggested to the producer's personal customers. The Medicinal Products Authorization Ordinance, which considers international standards, states that the manufacturer of pharmaceutical products must abide by the recognised standards of good manufacturing practise (GMP). The Ordinance directly refers to a few EU directives in a few places. If the fundamental operational and technological standards were satisfied and an appropriate quality assurance system was in place, a licence had to be issue [30].

**Marketing:** The fundamental guideline was that all commercially available medications and excipients must abide by all applicable Pharmacopoeial criteria. A set of requirements for the quality of medications, excipients, as well as particular medicinal diagnostics was known as Pharmacopoeia (also known as Pharmacopoeia European and Pharmacopoeia Helvetica).

**Only these Individuals may Prescribe Medicines that Require a Prescription:** Pharmacists; Medical experts; and properly qualified individuals working under their direction.

**Non-prescription Drugs may be distributed by:**

- Those authorised to dispense prescription medications (see above).
- Assistants in pharmacies.
- Properly qualified individuals under their control.
- Other appropriately qualified individuals who were dispensing medications within the scope of their licence.

A Swiss physician has published a licence that needs to be obtained by wholesalers of pharmaceuticals. Anybody supplying pharmaceuticals in a drugstore, pharmacy, or other retail trade establishment needed a cantonal licence. Everyone who produces, transfuses, or supplies blood or blood products must obtain an operating permit from the relevant authorities. Also, there were stringent prescription and dispensing requirements for veterinary medicines.

Swiss physicians served as the national authorization and supervisory authority for pharmaceuticals and medical products. The agency guarantees that only top-notch, secure, and effective medical items are available in Switzerland, making a substantial contribution to the protection of both human and animal health. The comparison study of various factors for India, Brazil, and Switzerland is given below [30] **Table 2.**

**TABLE 2: COMPARISION STUDY OF VARIOUS FACTORS IN INDIA, BRAZIL, SWITZERLAND**

| Parameters | India | Brazil | Switzerland |
|---|---|---|---|
| Regulatory authority | CDSCO | ANVISA | Swiss medic |
| Application for a clinical study | Form 44 was a request for permission to begin a clinical trail | Drug development dossier | Investigational medicinal product dossier |
| Fee for application | Fees were required in phase 1,2,3 which were $50,000,$25,000&$25,000 | Nearly $15,000 | Minor fees |
| Format for submitting an application | Form 44 must be submitted in accordance with rational guidelines | CTD format | CTD format |
| The deadline for approval | 16-18 weeks | 6-14 months | 17-20 weeks |

**CONCLUSION:** Every nation, including India, had extensive processes for examining and registering pharmaceuticals before they could be imported or exported. The outcome was that many imports were necessary for the fundamental goal of providing medication access to the general populace. It was necessary to consider a variety of regulatory standards, product licencing, and application forms for the production, importation, marketing, and sale of biologic products. ATMPs were medicinal products with a major impact on human health that were based on cells, tissues, and nucleic acids. The incorrect therapeutic classification, however, shows poor response since it only comprises goods with a limited diversity of therapeutic properties and bioactive ingredients. Sadly, other biological drugs with comparable physiological effects or mechanisms of action were not included. Using cutting-edge technical items with a comparable portfolio allocation, like those associated with transgenes, could have proven beneficial. There were two groups of ATMPs: low-risk and high-risk. The classification process carried out by a central committee of experts, which ultimately creates a beneficial system for the society, was a successful conclusion of this new regulation of ATMPs.

Brazilian laws on imported goods and sanitary monitoring items primarily govern pharmaceutical and food products. Imports intended for trade must receive ANVISA's approval before entering the nation, in accordance with the technological guidelines on imported items and goods for sanitary surveillance. It was difficult to ship pharmaceuticals to Brazil since registration takes a long time and all correspondence must be in that country's native tongue. Swiss physicians served as the organisation in charge of overseeing and regulating pharmaceuticals and medical devices. The organisation guarantees that only top-notch, secure, and effective medical supplies are imported into Switzerland. The requirements for approving a medicine as a Novel Pharmaceutical were much more stringent and exhaustive than just the glaringly inadequate standards for a medication that had already received approval. Exports and imports were crucial for the expansion and development of national economies because not all countries possess the knowledge and resources required to create particular goods and services.

**ACKNOWLEDGMENTS:** The authors thank the Management of Vikas Institute of Pharmaceutical Sciences for providing support for data collection.

**CONFLICT OF INTEREST:** Nil

## REFERENCES:

1. Sapoliya NK and Mamta BS: Regulations on Herbal Products in India, United States and European Union: A Review. International Journal of Drug Regulatory Affairs 2022; 10(2): 67-72.
2. Horner R: Global value chains, import orientation, and the state: South Africa’s pharmaceutical industry. Journal of International Business Policy 2022; 5: 68-87.
3. Handoo S, Arora V, Khera D, Nandi PK and Sahu SK: A comprehensive study on regulatory requirements for development and filing of generic drugs globally. International Journal of Pharmaceutical Investigation 2012; 2(3): 99-105.
4. Li E, Ramanan S and Green L: Pharmacist Substitution of Biological Products: Issues and Considerations. Journal of

Managed Care and Specialty Pharmacy 2015; 21(7): 532-539.
5. Senthil V, Priyadharshini BR, Ramachandran A, Ganesh GNK and Shrivastava A: Regulatory process for import and export of drugs in India. Internationl J of Pharmaceutical Sciences and Res 2015; 6(12): 4989-99.
6. Sangeetha VP, Remya NS and Mohanan PV: 12 - Regulatory issues in biological products. Biomedical Product and Materials Evaluation 2022; 309-327.
7. Chegu S and Nagabhushanam MV: A Comprehensive Study on Regulation of Herbal Drugs in India, US and European Union. International Journal of Drug Regulatory Affairs 2021; 9(1): 78-86.
8. Senthil V, Priyadharshini RB, Ramachandran A, Ganesh GNK and Shrivastava A: Regulatory Process for Import and Export of Drugs in India. International Journal of Pharmaceutical Sciences and Research 2015; 6(12): 4989-4999.
9. 12 Powerful Ayurvedic Herbs and Spices with Health Benefits. Healthline [Internet]. Available at https://www.healthline.com/nutrition/ayurvedic-herbs 2021 [cited 2021 Feb. 01].
10. Ayurvedic Herbs. [Internet]. Available at https://www.healthline.com/health/ayurvedic-herbs.
11. Ayurveda treatment a first choice: Need for more science. 2020 [cited 2021 Feb. 02]. [Internet]. Available at https://www.dnaindia.com/ahmedabad/column-ayurvedatreatment-a-first-choice-need-for-more-science-2694121.
12. Raj R: Import and Export of Drugs - Processor Aspects. International Journal of Economic Perspectives 2016; 10(1): 44-48.
13. Herbal Medicine. [Internet]. Available at https://en.wikipedia.org/wiki/Herbal_medicine.
14. European medicines agency EMEA. 2021 [cited 2021 Feb. 01]. [Internet]. Available at https://www.ema.europa.eu/en/human-regulatory/herbalproducts/herbal-medicines-regulatory-scientific-support.
15. Manoharan V, Ganesh GNK and Sruthi N: Regulatory Requirements for Registration of Drugs in Brazil. Journal of Critical Reviews 2020; 7(19): 5290-5295.
16. Eixarch H, Wyness L and Sibanda M: The Regulation of Personalized Cosmetics in the EU. Cosmetics 2019; 6(2): 1-5.
17. Singh A, Kalaivani M, Chaudhary P, Srivastava S, Goyal RK and Gupta SK: Opportunities and Challenges in Development of Phytopharmaceutical Drug in India- A SWOT Analysis. Journal of Young Pharmacists 2019; 11(3): 322-327.
18. Huynh-Ba K and Beumer Sassi A: ANVISA: an introduction to a new regulatory agency with many challenges. American Association of Pharmaceutical Scientists Open 2018; 4(9): 1-6.
19. Sheel SK: Problems of Export of Pharmaceutical Products from Bangladesh: An Analysis. Journal of Business Studies 2015; 36(3): 23-37.
20. Alostad AH, Steinke DT and Schafheutle EI: International Comparison of Five Herbal Medicine Registration Systems to Inform Regulation Development: United Kingdom, Germany, United States of America, United Arab Emirates and Kingdom of Bahrain. Pharmaceutical Medicine 2018; 32(1): 39-49.
21. Basak S: Pharmaceutical Market and Regulatory Contents for Export of Pharmaceutical Products to Latin American Countries. IOSR Journal of Business and Management 2018; 20(4): 16-26.
22. Basheer S and Kochupillai M: 'Exhausting' Patent Rights in India: Parallel Imports and TRIPS Compliance. Journal of Intellectual Property Rights 2008; 13: 486-497.
23. Reynolds EB, Zylberberg E and Victoria del Campo M: Brazil's role in the Biopharmaceutical Global Value Chain. MIT Industrial Performance Center 2016; 1-34.
24. Knezevic I and Griffiths E: WHO standards for biotherapeutics, including biosimilars: an example of the evaluation of complex biological products. Annals of the New York Academy of Sciences 2017; 1407(1): 5-16.
25. Mueller L and Costa SMT: Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil? Expert Opinion on Therapeutic Patents 2014; 24(1): 1-4.
26. Huynh-Ba K and Sassi AB: ANVISA: an introduction to a new regulatory agency with many challenges. American Association of Pharmaceutical Scientists Open 2018; 4(9): 1-6.
27. Angelino A, Khanh DT, An Ha N and Pham T: Pharmaceutical Industry in Vietnam: Sluggish Sector in a Growing Market. International Journal of Environmental Research and Public Health 2017 14(9): 1-18.
28. Pateriya S, Janodia MD, Deshpande PB, Ligade VS, Talole KB, Kulshrestha T, Kamariya Y, Musmade PB and Udupa N: Regulatory Aspects of Pharmaceuticals' Exports in Gulf Cooperation Council Countries. Journal of Young Pharmacists 2011; 3(2): 155–162.
29. Joseph L, George M, Malaviya KK, Chacko BK and Badjatya JK: Comparative study for generic drug approval process and their registration as per CTD in Europe, USA and Brazil. International Journal of Drug Regulatory Affairs 2016; 4(2): 1-9.
30. Sai Hanuja G, Sai Kumari B, Nagabhushanam MV, Nagarjuna Reddy D and Bonthagarala B: Regulatory requirements for registration of generic drugs in "BRICS" Countries. International Journal of Pharmaceutical Sciences and Health Care 2016; 6(6): 20-39.

**How to cite this article:**
Gnanakani SPE, Srilekha LN, Praneetha KPS and Sumalatha G: A comprehensive review on regulation concerns for import and export of pharmaceutical drugs and genetic products in India, Britain and Switzerland. Int J Pharm Sci & Res 2024; 15(1): 20-34. doi: 10.13040/IJPSR.0975-8232.15(1).20-34.